Vaginal Baclofen Suppositories in Chronic Pelvic Pain

Phase

Condition

Chronic Pelvic Pain

Interstitial Cystitis

Dysmenorrhea (Painful Periods)

Treatment

20 mg baclofen vaginal suppository daily per vagina

Placebo

Clinical Study ID

NCT05968937

22.1000

Ages 18-65
Female
Accepts Healthy Volunteers

Study Summary

The purpose of this study is to evaluate if baclofen vaginal suppositories improve symptoms of Chronic Pelvic Pain (CPP).

Participants in this study will take four short questionnaires prior to being randomized. Randomization is like flipping a coin; participants have an equal likelihood of being randomized to the treatment group (vaginal baclofen suppositories) or placebo group (vaginal suppository without baclofen ingredient). Participants will take their assigned treatment nightly for 8 weeks. Follow up visits will be at the 4 and 8 week time frames, when questionnaires will again be completed. Participants may receive additional treatments for CPP during the course of the study. After 8 weeks Participants will be offered a prescription for baclofen suppositories and the study drug will be stopped. Follow up on patient symptoms with questionnaires will again occur at 12 weeks.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Women ages 18-65 years old
Women are not sexually active, sexually active with same sex partners or are oneffective contraception
Diagnosed with Chronic Pelvic Pain

Exclusion

Exclusion Criteria:

Gross hematuria
Currently pregnant or breastfeeding
Unable to speak and read English
History of allergic reaction to baclofen tablet
History of allergic reaction to components of placebo (coconut oil)
History of gastrointestinal, genitourinary, or pelvic cancer in the last 5 years

Study Design

20 mg baclofen vaginal suppository daily per vagina

January 01, 2024

June 01, 2026

Study Description

Study Design/Methodology

This is a single center, double-blinded, placebo-controlled, randomized trial. Women will be recruited from a subspecialty clinic at the University of Louisville and be eligible for participation if they meet the diagnosis of Chronic Pelvic Pain and are between the ages of 18-65 years old. Eligible, consenting participants will undergo randomization with equal probability of assignment to one of the two groups:

Baclofen 20mg vaginal suppository daily per vagina and
placebo.

Participants will be blinded to study allocation. Baclofen or placebo suppositories will be continued to 8 weeks, at which time all participants will be offered a baclofen suppository prescription. Patients will then follow up at the 12 week mark and whether they continued baclofen suppositories and pill count will be recorded in addition to the below questionnaires.

Clinical outcomes and questionnaires will be assessed at baseline and after 4, 8, and 12 weeks of treatment. Participants will be randomized with a stratified block randomization scheme (with a random block size of 4, 6, and 8 participants).

Participants will be required to come in for at least 1 visit at 8 weeks to assess pelvic muscle dysfunction and perform pill count.

We hypothesize a significant change in PROMIS Pain Interference score, patient satisfaction, PROMIS global health scores, and PROMIS sexual function scores for patients assigned to the baclofen treatment arm.